Leiomyosarcoma — Trials

Leiomyosarcoma — Trials · CancerIndex

Clinical trials

Registered studies

135 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 38
Recruiting: 25
Ph III recruiting: 2
Growth YoY: —
Industry share: 16%
Top sponsor: National Cancer Institute (NCI)
Termination share: 40.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (23)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06088290	Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)(SaLuDo)	active not recruiting	Phase 3	469	PharmaMarINDUSTRY	12	Jun 18, 2026	clinicaltrials

Data updated 22 days agoSource updated Jun 18, 2026source: clinicaltrials